Honokiol.

Honokiol acts as a positive allosteric modulator at GABA-A receptors in receptor work, while theanine raises alpha band cortical activity and dampens glutamatergic signalling. They reach normal calm signalling from two different points, which is why evening formulas pair them.

Honokiol is a lipophilic biphenolic with low water solubility and poor oral bioavailability on its own. A medium chain triglyceride carrier keeps it solubilised through the gut, the standard formulation route for compounds with this profile.

Magnesium modulates GABA-A receptors and blocks the NMDA channel pore, a different site from honokiol's allosteric GABA-A action. The two levers sit alongside each other rather than duplicating one another.

Honokiol is one of the two principal biphenyl neolignans in magnolia bark and magnolol is the other, and they are isomers with overlapping GABA-A receptor activity. Whole bark supplies both, so combining them restores the natural ratio the isolate loses.

Apigenin binds the benzodiazepine site of the GABA-A receptor while honokiol modulates a distinct site on the same complex. Formulators combine them in evening formulas because they converge on one receptor without sharing a binding pocket.

Melatonin carries the timing signal through MT1 and MT2 receptors while honokiol acts on chloride channel gating, so one sets when and the other sets how deeply. That split is why they appear together in sleep formulas.

Phosphatidylserine reduces the size of an evening cortisol rise through hypothalamic feedback, which sits upstream of honokiol's receptor-level action. The pairing addresses two different points on the same wind-down.

Cysteine availability sets the rate of glutathione synthesis, and NAC supplies it, so the Nrf2 signal honokiol raises has more to work with. Signal plus substrate is a standard pairing in redox formulas.

Sulforaphane modifies cysteine residues on Keap1 to release Nrf2, while honokiol reaches the same transcription factor by a separate mechanism. Both raise the same battery of phase II enzymes.

Valerenic acid acts at the beta subunit of the GABA-A receptor and honokiol modulates the same complex at another site, so the calming effect adds. Stacking two GABA-A modulators should be disclosed as additive, not treated as independent.

Magnolol is honokiol's positional isomer and the two occur together in Magnolia officinalis bark in comparable amounts. Chen and colleagues studied a magnolol and honokiol blend as a single dietary intervention in laying hens, reporting on performance, hepatic lipid handling and intestinal morphology. Almost every magnolia bark extract delivers both, so isolated-honokiol data and bark-extract data are not the same evidence.

Honokiol is a lipophilic biphenolic neolignan with very low water solubility, so a dry powder in a capsule disperses poorly in gut fluid. Phospholipid complexes give the molecule an amphiphilic carrier that disperses into mixed micelles. This is delivery chemistry and it does not change what the molecule does once absorbed.

Lecithin is the common food-grade emulsifier used to disperse poorly water-soluble botanical actives. For a biphenol like honokiol it lowers interfacial tension and helps the material enter mixed micelles for uptake. It is a formulation aid rather than an active partner.

Honokiol is reported to act as a positive allosteric modulator at GABA-A receptors at a site distinct from the benzodiazepine site. Supplemental GABA acts on the same receptor family, although its own crossing of the blood-brain barrier is debated. Stacking two things aimed at the same receptor family produces additive calming, which is the direction worth flagging.

Chamomile's apigenin binds the benzodiazepine site on GABA-A receptors, while honokiol modulates the same receptor at a different site. Two positive modulators of one receptor complex add rather than substitute. Anyone combining evening botanicals should count the total.

Passionflower flavonoids act on GABAergic transmission and appear alongside magnolia bark in evening formulas. The interaction to note is additive drowsiness rather than a shared benefit. No combination study exists for the pair.

Lemon balm's rosmarinic acid fraction has been reported to inhibit GABA transaminase, the enzyme that breaks GABA down, which would raise GABA availability at the receptor honokiol modulates. The two routes converge on the same signal from different sides. The convergence is mechanistic and has not been tested as a combination.

Glycine is an inhibitory neurotransmitter in its own right at strychnine-sensitive glycine receptors, a different receptor family from GABA-A. Combining it with honokiol in an evening product stacks two inhibitory inputs. The additive direction is the point rather than any demonstrated synergy.

Caffeine blocks adenosine receptors and raises alertness, working against the GABA-A positive modulation honokiol contributes. Where both appear in one regimen the two pull in opposite directions on the same behavioural endpoint. This is an anti-synergy and is worth stating as one.

Honokiol is cleared rapidly by glucuronidation and sulfation, which is the main reason its systemic exposure is short-lived after an oral dose. Piperine slows glucuronidation and is added to poorly bioavailable botanical actives for that reason. The mechanism is established for piperine; the magnitude for honokiol has not been measured in people.

Both are phenolic radical scavengers, but honokiol partitions into the lipid phase and EGCG into the aqueous phase, so they cover different compartments. Blends pair them on that logic. There is no combination study behind the pairing.

Alpha-tocopherol terminates lipid peroxidation chains in membranes, the same compartment a lipophilic biphenol occupies. Tocopherol also protects an oil-based honokiol preparation from oxidation during shelf life. The second role is formulation, the first is network chemistry.

Ashwagandha root extract and magnolia bark are commonly combined in stress and sleep products. The two work through unrelated chemistry, withanolides versus a neolignan. The pairing is convention rather than a demonstrated interaction.

Tryptophan is the precursor for serotonin and then melatonin, a different pathway from the GABA-A modulation attributed to honokiol. Both appear in evening formulations and the effects on sleepiness add. No study has tested the two together.